



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
Liliane Goetsch et al.	)	Group Art Unit: 1645
Application No.: 10/735,916	)	Examiner:
Filed: December 16, 2003	)	Confirmation No.: 5622
For: NOVEL ANTI-IGS-IR ANTIBODIES	)	
AND USES THEREOF	)	

**FIRST INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.


The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

To assist the Examiner, the document is / documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date October 8, 2004

By:   
Norman H. Stepno  
Registration No. 22,716

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Complete if Known

# **FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 5

Application Number 10/735,916  
 Filing Date December 16, 2003  
 First Named Inventor Liliane Goetsch et al.  
 Examiner Name  
 Attorney Docket Number 017753-183

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	WO 01/88138	A1	PCT	11-22-2001	X						
	WO 02/053596	A2	PCT	07-11-2002	X						
	WO 96/40210	A1	PCT	12-19-1996	X						

## **NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Bartucci et al., "Differential Insulin-like Growth Factor I Receptor Signaling and Function in Estrogen Receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 Breast Cancer Cells", Cancer Research, September 15, 2001, pgs. 65747-6754, Vol. 61
	Putz et al., "Epidermal Growth Factor (EGF) Receptor Blockade Inhibits the Action of EGF, Insulin-like Growth Factor I, and a Protein Kinase A Activator on the Mitogen-activated Protein Kinase Pathway in Prostate Cancer Cell Lines", Cancer Research, January 1, 1999, pgs. 227-233, Vol. 59
	Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor", Molecular and Cellular Biology, July 1994, pgs. 4588-4595, Vol. 14, No. 7, American Society for Microbiology
	Cheatham et al., "Insulin Action and the Insulin Signaling Network", Endocrine Reviews, 1995, pgs. 117-142, Vol. 16, No. 2, The Endocrine Society
	Singer et al., "Optimal Humanization of 1B4, and Anti-CD18 Murine Monoclonal Antibody, is Achieved by Correct Choice of Human V-Region Framework Sequences", The Journal of Immunology, April 1, 1993, pgs. 2844-2857, Vol. 150, No. 7, The American Association of Immunologists
	Pastorino et al., "Doxorubicin-loaded Fab' Fragments of Anti-disialoganglioside Immunoliposomes Selectively Inhibit the Growth and Dissemination of Human Neuroblastoma in Nude Mice" Cancer Research, January 1, 2003, pgs. 86-92, Vol. 63
	Glennie et al., "Preparation and Performance of Bispecific F(ab'γ) <sub>2</sub> Antibody Containing Thioether-Linked Fab'γ Fragments", The Journal of Immunology, October 1, 1987, pgs. 2367-2374, Vol. 139, No. 7, The American Association of Immunologists
	Bebbington et al., "High-Level Expression of a Recombinant Antibody from Myeloma Cells using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker", Bio/Technology, February 1992, pgs. 169-175, Vol. 10
	Amit et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution", Science, August 15, 1986, pgs. 747-753, Vol. 233
	Caton et al., "Identical D Region Sequences Expressed by Murine Monoclonal Antibodies Specific for a Human Tumor-Associated Antigen", The Journal of Immunology, March 1, 1990, pgs. 1965-1968, Vol. 144, No. 5, The American Association of Immunologists

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO			<b>Complete if Known</b>		
<b>FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Application Number</b>	10/735,916	
			<b>Filing Date</b>	December 16, 2003	
			<b>First Named Inventor</b>	Liliane Goetsch et al.	
			<b>Examiner Name</b>		
<b>Sheet</b>	<b>2</b>	<b>of</b>	<b>5</b>	<b>Attorney Docket Number</b>	017753-183

### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Chothia et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins", J. Mol. Biol., 1987, pgs. 901-917, Vol. 196, Academic Press Limited
	Chothia et al., "Conformations of immunoglobulin hypervariable regions", Nature, December 1989, pgs. 877-883, Vol. 342, 21/28
	Sharon, "Structural Characterization of Idiotypes by using Antibody Variants Generated by Site-Directed Mutagenesis", The Journal of Immunology, June 15, 1990, pgs. 4863-4869, Vol. 144, No. 12, The American Association of Immunologists
	Connolly, et al., "Regulation of DU145 Human Prostate Cancer Cell Proliferation by Insulin-Like Growth Factors and its Interaction with the Epidermal Growth Factor Autocrine Loop", The Prostate, 1994, pgs. 167-175, Vol. 24, Wiley-Liss, Inc.
	Kabat, et al., "Identical V Region Amino Acid Sequences and Segments of Sequences in Antibodies of Different Specificities", The Journal of Immunology, September 1, 1991, pgs. 1709-1719, Vol. 147, No. 5, The American Association of Immunologists
	Laguzza et al., "New Antitumor Monoclonal Antibody-Vinca Conjugates LY203725 and Related Compounds: Design, Preparation, and Representative in Vivo Activity", J. Med. Chem., 1989, pgs. 548-555, Vol. 32, American Chemical Society
	Fisher et al., "Endometrial Cancer in Tamoxifen -Treated Breast Cancer Patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14", Journal of the National Cancer Institute, April 6, 1994, pgs. 527-537, Vol. 86, No. 7
	Guvakova et al., "Tamoxifen Interferes with the Insulin-like Growth Factor I Receptor (IGF-IR) Signaling Pathway in Breast Cancer Cells", Cancer Research, July 1, 1997, pgs. 2606-2610, Vol. 57
	Forbes, "The Control of Breast Cancer: The Role of Tamoxifen", Seminars in Oncology, February 1997, pgs. SI-5-SI-19, Vol. 24, No. 1, Suppl 1
	Kullberg et al., "Tumor-Cell Targeted Epidermal Growth Factor Liposomes Loaded with Boronated Acridine: Uptake and Processing", Pharmaceutical Research, February 2003, pgs. 229-236, Vol. 20, No. 2, Plenum Publishing Corporation
	Suresh et al., "[17] Bispecific Monoclonal Antibodies from Hybrid Hybridomas", Methods in Enzymology, 1986, pgs. 210-228, Vol. 121, Academic Press, Inc.
	Monfar et al., "Activation of pp70/85 S6 Kinases in Interleukin-2-Responsive Lymphoid Cells is Mediated by Phosphatidylinositol 3-Kinase and Inhibited by Cyclic AMP", Molecular and Cellular Biology, January 1995, pgs. 326-337, Vol. 15, No. 1, American Society for Microbiology
	Yamada et al., "Role of the Transmembrane Domain and Flanking Amino Acids in Internalization and Down-Regulation of the Insulin Receptor", The Journal of Biological Chemistry, February 17, 1995, pgs. 3115-3122, Vol. 270, No. 7, The American Society for Biochemistry and Molecular Biology, Inc.
	Ciardiello, "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents", Drugs, 2000, pgs. 25-32, 60 Suppl. 1, Adis International Limited
	Petersen et al., "The Human Immune Response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies", Cancer Research, 1991, pgs. 2286-2290, Vol. 51, Issue 9, American Association for Cancer Research (Abstract only)
	Laviola et al., "The Adapter Protein Grb10 Associates Preferentially with the Insulin Receptor as Compared with the IGF-I Receptor in Mouse Fibroblasts", J. Clin. Invest., March 1997, pgs. 830-837, Vol. 99, No. 5, The American Society for Clinical Investigation, Inc.
	Masquelier et al., "Amino Acid and Peptide Derivatives of Daunorubicin. 1. Synthesis, Physicochemical Properties, and Lysosomal Digestion", J. Med. Chem., 1980, pgs. 1166-1170, Vol. 23, American Chemical Society
	Mariette et al., "Nucleotide Sequence Analysis of the V <sub>L</sub> and V <sub>H</sub> Domains of Five Human IgM Directed to Lamin B", Arthritis & Rheumatism, September 1993, pgs. 1315-1324, Vol. 36, No. 9, American College of Rheumatology

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO			<b>Complete if Known</b>		
<b>FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Application Number</b>	10/735,916	
			<b>Filing Date</b>	December 16, 2003	
			<b>First Named Inventor</b>	Liliane Goetsch et al.	
			<b>Examiner Name</b>		
<b>Sheet</b>	<b>3</b>	<b>of</b>	<b>5</b>	<b>Attorney Docket Number</b>	017753-183

NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Hailey et al., "Neutralizing Anti-Insulin-like Growth Factor Receptor 1 Antibodies Inhibit Receptor Function and Induce Receptors Degradation in Tumor Cells," Molecular Cancer Therapeutics, December 2002, pgs. 1349-1353, Vol. 1
	Kraus-Berthier et al., "Histology and Sensitivity to Anticancer Drugs of Two Human Non-Small Cell Lung Carcinomas Implanted in the Pleural Cavity of Nude Mice", Clinical Cancer Research, January 2000, pgs. 297-304, Vol. 6
	Schneck et al., "Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas", Clin Pharmacol Ther., January 1990, pgs. 36-41, Vol. 47, No. 1
	Ojima et al., "Tumor-Specific Novel Taxoid-Monoclonal Antibody Conjugates", J. Med. Chem., 2002, pgs. 5620-5623, Vol. 45, American Chemical Society
	Sharon, "Structural correlates of high antibody affinity: Three engineered amino acid substitutions can increase the affinity of an anti- <i>p</i> -azophenylarsonate antibody 200-fold", Proc. Natl. Acad. Sci./Immunology, June 1990, pgs. 4814-4817, Vol. 87
	Burrow et al., "Expression of Insulin-Like Growth Factor Receptor, IGF-1, and IGF-2 in Primary and Metastatic Osteosarcoma", Journal of Surgical Oncology, 1998, pgs. 21-27, Vol. 69, Wiley-Liss, Inc.
	Petruzzi et al., "Prior Cocaine Exposure in Different Environments Affects the Behavioral Responses of Mouse Dams", Pharmacology Biochemistry and Behavior, 1997, pgs. 541-547, Vol. 56, No. 3, Elsevier Science Inc.
	Myers et al., "Common and Distinct Elements in Insulin and PDGF Signaling", Annals New York Academy of Sciences, pgs. 369-387
	Valentinis et al., "Growth and Differentiation Signals by the Insulin-like Growth Factor 1 Receptor in Hemopoietic Cells are Mediated through Different Pathways", The Journal of Biological Chemistry, April 30, 1999, pgs. 12423-12430, Vol. 274, No. 18, The American Society for Biochemistry and Molecular Biology, Inc.
	Salomon et al., "Epidermal growth factor-related peptides and their receptors in human malignancies", Critical Reviews in Oncology/Hematology, 1995, pgs. 183-232, Vol. 19, Elsevier Science Ireland Ltd.
	Lee et al., "Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression <i>in Vitro</i> and <i>in Vivo</i> ", Molecular Endocrinology, 1999, pgs. 787-796, Vol. 10, No. 5, The Endocrine Society
	Kuehne et al., "Syntheses of 20'-Deoxyvinblastine, 20'-Deoxyvincovaline, 20'- <i>epi</i> -20'-Deoxyvincovaline, and 20'-Deoxyvincristine and its 20'-Epimer through Racemic and Enantioselectively Generated Intermediates. New Syntheses of <i>D/E-cis</i> and <i>-trans-Ψ</i> -Vincadifformines and <i>D/E-cis</i> and <i>-trans-20-epi-Ψ</i> -Vincadifformines", J. Org. Chem., 1989, pgs. 3407-3420, Vol. 54, 1989 American Chemical Society
	Duflos et al., "Novel Aspects of Natural and Modified <i>Vinca</i> Alkaloids", Curr. Med. Chem. - Anti-Cancer Agents, 2002, pgs. 55-70, Vol. 2, Bentham Science Publishers Ltd.
	Beech et al., "Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol", Oncology Reports, 2001, pgs. 325-329, Vol. 8
	Railo et al., "The Prognostic Value of Insulin-like Growth Factor-I in Breast Cancer Patients. Results of a Follow-up Study on 126 Patients", European Journal of Cancer, 1994, pgs. 307-311, Vol. 30A, No. 3, Elsevier Science Ltd.
	Wraight et al., "Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides", Nature Biotechnology, May 2000, pgs. 521-526, Vol. 18
	Harding et al., "Immunogenicity and pharmacokinetic attributes of poly(ethyleneglycol)-grafter immunoliposomes", Biochimica et Biophysica Acta, 1997, pgs. 181-192, Vol. 1327, Elsevier Science B.V.
	Pietrzkowski et al., "Constitutive Expression of Insulin-like Growth Factor 1 and Insulin-like Growth Factor 1 Receptor Abrogates All Requirements for Exogenous Growth Factors", Cell Growth & Differentiation, April 1992, pgs. 199-205, Vol. 3
	Zenni et al., " <i>Streptococcus pneumoniae</i> colonization in the young child: Association with otitis media and resistance to penicillin", The Journal of Pediatrics, October 1995, pgs. 533-537, Mosby-Year Books, Inc.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO			<b>Complete if Known</b>		
<b>FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Application Number</b>	10/735,916	
			<b>Filing Date</b>	December 16, 2003	
			<b>First Named Inventor</b>	Liliane Goetsch et al.	
			<b>Examiner Name</b>		
<b>Sheet</b>	<b>4</b>	<b>of</b>	<b>5</b>	<b>Attorney Docket Number</b>	017753-183

NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Jones et al., "Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions", Bio/Technology, January 1991, pgs. 88-89, Vol. 9
	Alessi et al., "Characterization of a 3-phosphoinositide-dependant protein kinase which phosphorylates and activates protein kinase B $\alpha$ ", Current Biology, March 19, 1997, pgs. 261-269, Vol. 7, No. 4, Current Biology, Ltd.
	Alessi et al., "3-Phosphoinositide-dependant protein kinase-1 (PDK1): structural and functional homology with the <i>Drosophila</i> DSTPK61 kinase", Current Biology, September 18, 1997, pgs. 776-789, Vol. 7, No. 10, Current Biology, Ltd.
	Cavestri et al., "Access to rehabilitation facilities in an unselected hospital population affected by acute stroke", Ital. J. Neurol. Sci., October 1996, pgs. 9-16, Vol. 18
	Sell et al., "Effect of a Null Mutation of the Insulin-Like Growth Factor I Receptor Gene on Growth and Transformation of Mouse Embryo Fibroblasts", Molecular and Cellular Biology, June 1994, pgs. 3604-3612, Vol. 14, No. 6
	Sell et al., "Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor", Proc. Natl. Acad. Sci. USA/Cell Biology, December 1993, pgs. 11217-11221, Vol. 90
	Sachdev et al., "A Chimeric Humanized Single-Chain Antibody against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-I", Cancer Research, February 1, 2003, pgs. 627-635, Vol. 53
	Staerz et al., "Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity", Proc. Natl. Acad. Sci. USA/Immunology, March 1986, pgs. 1453-1457, Vol. 83
	Morrione et al., "Failure of the Bovine Papillomavirus to Transform Mouse Embryo Fibroblasts with a Targeted Disruption of the Insulin-Like Growth Factor I Receptor Genes", Journal of Virology, September 1995, pgs. 5300-5303, Vol. 69, No. 9, American Society for Microbiology
	Mountain et al., "Engineering Antibodies for Therapy", Biotechnology and Genetic Engineering Reviews, December 1992, pgs. 1-142, Vol. 10, Intercept Ltd., UK
	Smith et al., "Comparison of Biosequences", Advances in Applied Mathematics, 1981, pgs. 482-489, Vol. 2, Academic Press, Inc
	Needleman et al., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", J. Mol. Biol. 1970, pgs. 443-453, Vol. 48
	Carter, "Improving The Efficacy of Antibody-Based Cancer Therapies", Nature Reviews, November 2001, pgs. 118-129, Vol. 1
	Pearson et al., "Improved tools for biological sequence comparison", Proc. Natl. Acad. Sci. USA, April 1988, pgs. 2444-2448, Vol. 85
	Herbst et al., "Epidermal Growth Factor Receptors as a Target for Cancer Treatment: The Emerging Role of IMC-C225 in the Treatment of Lung and Head and Neck Cancers", Seminars in Oncology, February 2002, pgs. 27-36, Vol. 29, No. 1, Suppl. 1, Elsevier Science (USA)
	Benson et al., "Information Disclosure, Subject Understanding, and Informed Consent in Psychiatric Research", Law and Human Behavior, 1988, pgs. 455-475, Vol. 12, No. 4, Plenum Publishing Corporation
	Benson et al., "Trends in the Social Control of Medical and Psychiatric Research", pgs. 1-47
	Cirulli et al., "Sexual segregation in infant mice: behavioral and neuroendocrine response to <i>d</i> -amphetamine administration", Psychopharmacology, 1997, pgs. 140-152, Vol. 134, Springer-Verlag
	Arteaga et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice", J. Clin. Invest., November 1989, pgs. 1418-1423, Vol. 84, The American Society for Clinical Investigation, Inc.
	Holliger et al., "Engineering antibodies for the clinic", Cancer and Metastasis Reviews, 2000, pgs. 411-419, Vol. 18, Kluwer Academic Publishers, Netherlands

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO			<b>Complete if Known</b>		
<b>FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Application Number</b>	10/735,916	
			<b>Filing Date</b>	December 16, 2003	
			<b>First Named Inventor</b>	Liliane Goetsch et al.	
			<b>Examiner Name</b>		
<b>Sheet</b>	<b>5</b>	<b>of</b>	<b>5</b>	<b>Attorney Docket Number</b>	017753-183

NON-PATENT LITERATURE DOCUMENTS	
<b>Examiner Initials</b>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	King et al., "Heath Teaching for People with Disabilities", Home Healthcare Nurse, 1995, pgs. 52-58, Vol. 13, No. 6, Lippincott-Raven Publishers
	Grothey et al., "The role of Insulin-Like Growth Factor I and its receptors in cell growth, transformation, apoptosis, and chemoresistance in solid tumors", J. Cancer Res. Clin. Oncol., 1999, pgs. 166-173, Vol. 125, Springer-Verlag
	Garnett, "Targeted drug conjugates: principles and progress", Advanced Drug Delivery Reviews, 2001, pgs. 171-216, Vol. 53, Elsevier Science B.V.
	Roth et al., "Electroconvulsive Therapy in a Patient with Mania, Parkinsonism, and Tardive Dyskinesia", Convulsive Therapy, 1988, pgs. 92-97, Vol. 4, No. 1, Raven Press, Ltd., New York
	Pagani et al., "The Management of Tetralogy of Fallot with Pulmonary Atresia and Diminutive Pulmonary Arteries", The Journal of Thoracic and Cardiovascular Surgery, 1999, pgs. 1521-1533, Vol. 110, No. 5, Mosby-Year Book, Inc.
	Cheatham et al., "A Meta-Analysis of Selective <i>Versus</i> Routine Nasogastric Decompression After Elective Laparotomy, Annals of Surgery, 1995, pgs. 469-478, Vol. 221, No. 5, J. B. Lippincott Company
	Tatusova et al., "BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences", FEMS Microbiology Letters, 1999, pgs. 247-250, Vol. 174, Elsevier Science B.V.
	Park et al., "Generation and Characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens", Molecular Immunology, 2001, pgs. 1123-1130, Vol. 37, Elsevier Science Ltd.
	Ammirati et al., "The Endolymphatic Sac: Microsurgical Topographic Anatomy", Neurosurgery, February 1995, pgs. 416-419, Vol. 36, No. 2
	Surmacz et al., "Type I Insulin-Like Growth Factor Receptor Function in Breast Cancer", Breast Cancer Research and Treatment, 1998, pgs. 225-267, Vol. 47, Kluwer Academic Publishers, Netherlands
	Hakam et al., "Expression of Insulin-Like Growth Factor 1 Receptor in Human Colorectal Cancer", Human Pathology, 1999, pgs. 1128-1133, Vol. 30, No. 10, W.B. Saunders Company
	Hurwitz et al., "Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies", Cancer Immunol Immunother, 2000, pgs. 226-234, Vol. 49, Springer-Verlag
	Lu et al., "Insulin-Like Growth Factor I Receptor Signaling and Resistance to Trastuzumab (Herceptin)", Journal of the National Cancer Institute, December 19, 2001, pgs. 1852-1857, Vol. 93, No. 24, Oxford University Press
	Li et al., "Single-chain antibodies against human Insulin-Like Growth Factor I receptor: expression, purification, and effect on tumor growth", Cancer Immunol Immunother, 2000, pgs. 243-253, Vol. 49, Springer-Verlag
	Cheatham et al., "Structural and functional analysis of pp70 <sup>S6Kp</sup> ", proc. Natl. Acad. Sci/Cell Biology, December 1995, pgs. 11696-11700, Vol. 92
	Chang et al., "Insulin Stimulation of Mitogen-activated Protein Kinases, p90 <sup>RSK</sup> , and p70 S6 Kinase in Skeletal Muscle of Normal and Insulin-resistant Mice", The Journal of Biological Chemistry, December 15, 1995, pgs. 29928-29935, Vol. 270, No. 50, The American Society for Biochemistry and Molecular Biology, Inc.
	International Search Report corresponding to PCT FR 03/00178, issued on November 13, 2003, 3 pages

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.